1
|
Ren J, Zhao C, Sun R, Sun J, Lu L, Wu J, Li S, Cui L. Augmented drug resistance of osteosarcoma cells within decalcified bone matrix scaffold: The role of glutamine metabolism. Int J Cancer 2024; 154:1626-1638. [PMID: 38196144 DOI: 10.1002/ijc.34841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 11/07/2023] [Accepted: 12/19/2023] [Indexed: 01/11/2024]
Abstract
Due to the lack of a precise in vitro model that can mimic the nature microenvironment in osteosarcoma, the understanding of its resistance to chemical drugs remains limited. Here, we report a novel three-dimensional model of osteosarcoma constructed by seeding tumor cells (MG-63 and MNNG/HOS Cl no. 5) within demineralized bone matrix scaffolds. Demineralized bone matrix scaffolds retain the original components of the natural bone matrix (hydroxyapatite and collagen type I), and possess good biocompatibility allowing osteosarcoma cells to proliferate and aggregate into clusters within the pores. Growing within the scaffold conferred elevated resistance to doxorubicin on MG-63 and MNNG/HOS Cl no. 5 cell lines as compared to two-dimensional cultures. Transcriptomic analysis showed an increased enrichment for drug resistance genes along with enhanced glutamine metabolism in osteosarcoma cells in demineralized bone matrix scaffolds. Inhibition of glutamine metabolism resulted in a decrease in drug resistance of osteosarcoma, which could be restored by α-ketoglutarate supplementation. Overall, our study suggests that microenvironmental cues in demineralized bone matrix scaffolds can enhance osteosarcoma drug responses and that targeting glutamine metabolism may be a strategy for treating osteosarcoma drug resistance.
Collapse
Affiliation(s)
- Jiaxin Ren
- Department of Reconstructive and Regenerative Surgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
- Department of Stem Cells and Regenerative Medicine, Tongji University School of Medicine, Shanghai, China
| | - Cheng Zhao
- Department of Reconstructive and Regenerative Surgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
- Department of Stem Cells and Regenerative Medicine, Tongji University School of Medicine, Shanghai, China
| | - Ruizhu Sun
- Department of Reconstructive and Regenerative Surgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
- Department of Stem Cells and Regenerative Medicine, Tongji University School of Medicine, Shanghai, China
| | - Jian Sun
- Department of Reconstructive and Regenerative Surgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
| | - Laiya Lu
- Department of Stem Cells and Regenerative Medicine, Tongji University School of Medicine, Shanghai, China
| | - Jun Wu
- CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
| | - Shuaijun Li
- Department of Reconstructive and Regenerative Surgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
- Department of Stem Cells and Regenerative Medicine, Tongji University School of Medicine, Shanghai, China
| | - Lei Cui
- Department of Reconstructive and Regenerative Surgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
- Department of Stem Cells and Regenerative Medicine, Tongji University School of Medicine, Shanghai, China
| |
Collapse
|
2
|
Zhang L, Jia B, Velu P, Wu H. Corilagin induces apoptosis and inhibits HMBG1/PI3K/AKT signaling pathways in a rat model of gastric carcinogenesis induced by methylnitronitrosoguanidine. Environ Toxicol 2022; 37:1222-1230. [PMID: 35103375 DOI: 10.1002/tox.23478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Revised: 01/07/2022] [Accepted: 01/16/2022] [Indexed: 06/14/2023]
Abstract
Gastric cancer, invasive cancer of the gastrointestinal tract, found in developing countries. Chemotherapy to patients with advanced gastric cancer, exhibits greater drug resistance to standard chemotherapy drugs. Therefore, important to establish anti-cancer drugs that are successful for cancer therapy. Corilagin is a natural ellagitannin (ET) with profound pharmacological properties has been used for the study to assess its anticancer effects against N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) stimulated gastric cancer rats. Biochemical studies showed Thiobarbituric acid reactive substances (TBARS) and enzymatic and non-enzymatic antioxidants increased in corilagin treated animals compared with controls. Histopathologic evaluation revealed corilagin treated rats showed cell morphology similar that control showing its ameliorating effects. In corillagen treament mRNA protein expression levels of HIF-1α, AKT, PI3K, CT4, CD147 and HMGB1 were drastically lowered transcription factors triggering gastric cancer. In Western blot analysis showed released higher apoptotic marker of caspase-3, -9, Bax while Bcl-2 levels were significantly reduced confirming that corilagin triggers apoptosis in gastric cancer.
Collapse
Affiliation(s)
- Li Zhang
- Department of Geriatrics, Xi'an Hospital of Traditional Chinese Medicine, Xi'an, China
| | - Bingxin Jia
- Department of General Surgery (No.2), Yulin Traditional Chinese Medicine Hospital, Yulin, China
| | - Periyannan Velu
- Research Associate, Muthayammal College of Arts and Science, Rasipuram, Tamil Nadu, India
| | - Hong Wu
- Department of General Surgery, Xian XD Group Hospital, Xi'an, China
| |
Collapse
|
3
|
Abstract
At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance. With a number of novel targeted agents showing activity in the setting of metastatic RCC, there has been great interest in exploring the potential of the same agents in the adjuvant setting. Herein, we discuss the evolution of adjuvant trials in RCC, spanning from the immunotherapy era to the targeted therapy era. Pitfalls of current studies are addressed to provide a context for interpreting forthcoming results. Finally, we outline avenues to incorporate promising investigational agents, such as PD-1 (programmed death-1) inhibitors and MNNG transforming gene inhibitors, in future adjuvant trials.
Collapse
Affiliation(s)
- Sumanta K Pal
- Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA; Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Naomi B Haas
- Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA; Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| |
Collapse
|
4
|
Maki Y, Murakami J, Asaumi JI, Tsujigiwa H, Nagatsuka H, Kokeguchi S, Fukui K, Kawai N, Yanagi Y, Kuroda M, Tanaka N, Matsubara N, Kishi K. Role of O6-methylguanine–DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines. Oral Oncol 2005; 41:984-93. [PMID: 16043385 DOI: 10.1016/j.oraloncology.2005.05.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2005] [Accepted: 05/27/2005] [Indexed: 11/17/2022]
Abstract
The DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) modulates the effectiveness of alkylating agents. However, the relationship between MGMT and the sensitivities to other agents has not been explored. In the present study, the association between MGMT expression and the cellular sensitivity to the platinum agent, CDDP was examined in four human oral cancer cell lines. CDDP depleted MGMT protein and mRNA levels in all four cell lines. Two cell lines with low MGMT expression were sensitive to an alkylating agent, N-methyl-N'-nitro-N-nitrosoguanidine and CDDP, whereas two other cell lines with high MGMT expression were resistant to both agents. Furthermore, the addition of the MGMT inhibitor, O6-benzylguanine (O6-BG), invariably enhanced CDDP sensitivity. CDDP depleted MGMT expression, and CDDP sensitivity was enhanced by O6-BG. These results provide valuable information about the relationship between MGMT expression and CDDP sensitivity in oral cancer chemotherapy.
Collapse
Affiliation(s)
- Yu Maki
- Department of Oral and Maxillofacial Radiology, Field of Tumor Biology, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama 700-8525, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Siesjö P, Visse E, Lindvall M, Salford L, Sjögren HO. Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts. Cancer Immunol Immunother 1993; 37:67-74. [PMID: 8513454 PMCID: PMC11038449 DOI: 10.1007/bf01516944] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/1992] [Accepted: 01/06/1993] [Indexed: 01/31/2023]
Abstract
The ethyl-N-nitrosourea-induced rat glioma N32 was treated with the mutagenic compound N-methyl-N'-nitro-N-nitrosoguanidine and the surviving cells cloned by limited dilution. Out of 20 clones tested 8 did not produce tumors subcutaneously even after challenge doses 3 log units above the minimal tumor dose for N32. All of 5 clones grew in a retarded manner intracerebrally but produced tumors in some animals. Preimmunizations with three of the rejected clones (tum-) gave protection against subcutaneous and intracerebral isografts of the unmutated N32. This effect could be enhanced if the cells used for immunizations were pretreated with interferon gamma (IFN gamma) for 48 h. If immunizations were started subsequent to challenge, only immunization with one of two tested tum- clones pretreated with IFN gamma induced significant rejection against intracerebral N32 isografts. Both N32 and its tum- clones were MHC class I positive and MHC class II negative. IFN gamma treatment enhanced the MHC class I expression with 20%-90% on the tum- clones and with 40% on N32. MHC class II expression could be induced on N32 cells after 7 days of IFN gamma treatment but not on any of the tum- clones tested. We conclude that the enhancing effect of IFN gamma treatment on tumor isograft rejection may depend on up-regulation of MHC class I but not of MHC class II. This investigation demonstrates that it is possible to induce rejection of weakly immunogenic intracerebral brain tumors by immunization with selected highly immunogenic tumor cell mutants. In conjunction with relevant cytokines, the cross-protective effect of these tum- variants might be further enhanced and serve as a model for immunotherapy against malignant human brain tumors.
Collapse
Affiliation(s)
- P Siesjö
- Department of Tumorimmunology, Wallenberg Laboratory, University of Lund, Sweden
| | | | | | | | | |
Collapse
|
6
|
Maruyama K, Mochizuki S, Kawamura K, Tamayama C. Autonomous growth of human T-lymphotropic virus type I infected human lymphocytes treated with N-methyl-N'-nitro-N-nitrosoguanidine and ultraviolet rays. J Leukoc Biol 1991; 50:341-8. [PMID: 1919362 DOI: 10.1002/jlb.50.4.341] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Human T-cell cultures infected with human T-lymphotropic virus type I (HTLV-I) and interleukin-2 (IL-2)-dependent for their continuous growth were treated with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and then maintained in the medium containing phorbol 12-myristate 13-acetate (TPA). Cells achieved independence from IL-2 but became TPA-dependent for continuous growth. Multiple ultraviolet (UV) irradiations of TPA-dependent cells resulted in their autonomous growth. G-band karyotype analysis revealed multiple chromosomal abnormalities that were seen in cells before and after MNNG treatment and UV irradiations, and those that were only seen in autonomously growing cells. Viral expression was found to be transiently enhanced in association with emergence of certain chromosomal changes. Exposure of HTLV-I infected cells to certain mutagens may promote the occurrence of the specific rearrangement of cellular genes responsible for regulation of cellular and viral replication and may lead these cells to neoplastic transformation.
Collapse
Affiliation(s)
- K Maruyama
- Department of Pathology, Chiba Cancer Center Research Institute, Japan
| | | | | | | |
Collapse
|
7
|
Frost P, Kerbel RS, Bauer E, Tartamella-Biondo R, Cefalu W. Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res 1983; 43:125-32. [PMID: 6401163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
8
|
Schabel FM. Nitrosoureas: a review of experimental antitumor activity. Cancer Treat Rep 1976; 60:665-98. [PMID: 782694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The chemical class of drugs known as the nitrosoureas are a recently developed group of very active alkylating-agent anticancer drugs which are best represented by BCNU, CCNU, and methyl-CCNU (meCCNU). The nitrosoureas are among the most active, if not the most active, anticancer drugs both quantitatively (log kill of sensitive tumor cells in vivo) and qualitatively (spectrum of mouse, rat, and hamster tumors responding to treatment). Therapeutic anticancer activity of the nitrosoureas has been consistently observed with oral as well as parenteral administration. The nitrosoureas are clearly the most active group of anticancer drugs observed against experimental meningeal leukemias and intracerebrally implanted transplantable primary tumors of central nervous system origin (eg, gliomas, ependymoblastomas, and astrocytomas in mice and hamsters). The nitrosoureas have been observed to be less than additive in lethal toxicity for vital normal cells in the mouse in combination with representatives of the other major classes of anticancer agents, eg, purine antagonists, pyrimidine antagonists, inhibitors of DNA polymerase(s) or ribonucleotide reductase(s), mitotic inhibitors, drugs that bind to or intercalate with DNA, and other alkylating agents. Therapeutic synergism against one or more transplantable or spontaneous tumors of mice, rats, or hamsters with one of several nitrosoureas in two-drug combinations with representatives of most of the major classes of anticancer agents listed above has been reported. With a number of advanced-stages mouse tumors, generally considered to be refractory to treatment with most anticancer agents, long-term cures have been obtained with combination-drug or combined-modality (surgery plus chemotherapy) treatment. The demonstrated lack of cross-resistance of several leukemias and solid tumors of mice selected for resistance to BCNU, meCCNU, or other alkylating agents suggests that the widely held opinion that all alkylating agents are very similar in biologic mechanism of action, and therefore resistance to one alkylating agent probably predicts cross-resistance to all alkylating agents, may no longer be tenable. If not, then alkylating-agent drug combinations, either used alone or combined with other treatment modalities (eg, surgery) which have been reported to result in therapeutic improvement in a number of experimental murine tumor systems, may be indicated for serious consideration as surgical adjuvant chemotherapy by surgeons or as primary therapy by medical oncologists.
Collapse
|
9
|
Schepartz SA. Early history and development of the nitrosoureas. Cancer Treat Rep 1976; 60:647-9. [PMID: 782693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|